Industry Veteran Herman Cueto Named
CFO
Azenta CFO Lindon
Robertson to Retire
Company Reaffirms Guidance for Fourth Quarter
Fiscal 2023
BURLINGTON, Mass., Sept. 26,
2023 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA)
today announced that Herman Cueto
will join Azenta as Executive Vice President and Chief Financial
Officer, effective October 16.
Mr. Cueto, who comes from BD (Becton, Dickinson and Company,
NYSE: BDX), will succeed Azenta CFO Lindon
Robertson, who is retiring and will remain as an advisor to
facilitate a seamless transition.
Steve Schwartz, Azenta President
and Chief Executive Officer, said, "We are thrilled to welcome
Herman to Azenta. He brings a combination of extensive industry
experience and finance expertise, including developing and
executing strategies to reduce complexity and enhance value. I look
forward to collaborating with him as we work to accelerate revenue
growth, drive sustainable margin expansion and create value for
shareholders as a pure-play life sciences company."
Mr. Cueto joins Azenta from BD, which he joined in 2017 through
its acquisition of CR Bard. Mr. Cueto most recently served at
BD as Senior Vice President of Finance, overseeing Segments /
Regions / BP&A / Operations. He formerly served as Senior Vice
President and Chief Financial Officer of BD's Medical Segment,
BD's largest operating unit, as well as overseeing finance's
functional responsibility for Operations and Global Supply Chain.
Prior, Mr. Cueto was at CR Bard for fourteen years, most recently
as Vice President and Group CFO. He earned a Bachelor of Science
and master's degree from Fairleigh Dickinson
University and a Master of Business Administration degree
from Seton Hall University. Mr. Cueto
is also a Certified Public Accountant licensed in the State of New Jersey.
Mr. Cueto said, "I am excited to join Azenta at such a pivotal
time for the Company and its industry. Azenta is known for its
cutting-edge, life sciences technology and unique role in the
sample management ecosystem. I look forward to working closely with
Steve and team as Azenta continues to enable breakthroughs faster
and bring essential therapies to those who need them most."
Dr. Schwartz continued, "On behalf of the Board, management team
and entire Company, we thank Lindon for his tremendous
contributions to Azenta over the past decade. He has been
instrumental in our financial and strategic positioning as we
transformed from a small business within Brooks Automation, to a
pure-play, publicly-traded life sciences company generating more
than $600 million in revenue. We are
grateful to Lindon for his leadership and wish him all the
best in his retirement."
Company Reaffirms Fourth Quarter Fiscal 2023 Guidance
Azenta is reaffirming its fourth quarter fiscal 2023 guidance
provided in its third quarter 2023 earnings materials on
August 8, 2023.
About Azenta Life Sciences
Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life
sciences solutions worldwide, enabling impactful breakthroughs and
therapies to market faster. Azenta provides a full suite of
reliable cold-chain sample management solutions and multiomics
services across areas such as drug development, clinical research
and advanced cell therapies for the industry's top pharmaceutical,
biotech, academic and healthcare institutions globally.
Azenta is headquartered in Burlington,
MA, with operations in North
America, Europe and
Asia. For more information, please
visit www.azenta.com.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are forward-looking statements
made under Section 21E of the Securities Exchange Act of 1934.
These statements are neither promises nor guarantees but involve
risks and uncertainties, both known and unknown, that could cause
Azenta's financial and business results to differ materially from
our expectations. They are based on the facts known to management
at the time they are made. Other forward-looking statements include
but are not limited to statements about our revenue and earnings
expectations and otherwise related to future operating or financial
performance and opportunities. Factors that could cause results to
differ from our expectations include the following: our ability to
reduce costs effectively, the impact of the COVID-19 global
pandemic on the markets we serve, including our supply chain, and
on the global economy generally; the volatility of the life
sciences markets the Company serves; our possible inability to meet
demand for our products due to difficulties in obtaining components
and materials from our suppliers in required quantities and of
required quality; the inability of customers to make payments to us
when due; price competition; disputes concerning intellectual
property; uncertainties in global political and economic
conditions; our ability to successfully invest the cash proceeds
from the sale of our Semiconductor Automation business; and other
factors and other risks, including those that we have described in
our filings with the Securities and Exchange Commission, including
but not limited to our Annual Report on Form 10-K, Current Reports
on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we
can provide no assurance that our future results will not be
materially different from those projected. Azenta expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any such statement to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which any such statement is based. Azenta
undertakes no obligation to update the information contained in
this press release.
INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations & Corporate Communications
ir@azenta.com
Sherry Dinsmore
sherry.dinsmore@azenta.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/azenta-announces-cfo-transition-301938247.html
SOURCE Azenta